Company Analysis
Sign in

Regeneron Pharmaceuticals, Inc. (REGN)

Nasdaq: REGN · Pharmaceutical Preparations · Tarrytown, NY · filing with the SEC since 1995
Full chart Alerts Compare
Grade7.3
◀ Past 7.9● Present 8.5▶ Future 5.0
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1,433 patents granted to the 9 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Regeneron Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
1,433
1,411 utility, 20 design, 2 reissue, 1976 to Dec 31, 2025
Granted in 2025
172
Against 166 in 2024 and 142 in 2023
Applications published
2,346
246 of them in 2025
Names they are printed under
9
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology287
Pharmaceuticals259
Measurement58
Medical technology30
Analysis of biological materials27
Computer technology19
Electrical machinery, apparatus, energy7
Other special machines6
Chemical engineering6
Handling3
Basic communication processes1
Mechanical elements1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name9 counted
Regeneron Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
1,412 granted
735 published
Regeneron Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in TW)
0 granted
1,553 published
Decibel Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
36 published
CHECKMATE PHARMACEUTICALS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
11 published
Decibel Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
10 granted
1 published
Oxular Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
10 published
CHECKMATE PHARMACEUTICALS, INC. a subsidiary
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
5 granted
0 published
Oxular Limited a subsidiary
GB, as the owner printed on each patent
5 granted
0 published
Oxular Acquisitions Limited a subsidiary
GB, as the owner printed on each patent
1 granted
0 published
Names not counted (2)
RV Holding Corp.
Most of its patents print NL; this name counts in US. 1 granted and 0 published under it are not counted.
RV Holding Corp.
Most of its patents print NL; this name counts in US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,510,521Devices and systems for chromatography column bed support management and related methodsMeasurementRegeneron Pharmaceuticals, Inc.
Dec 30, 202512,509,687Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitorsBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 30, 202512,509,516Heavy chain constant regions with reduced binding to Fc gamma receptorsBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 30, 202512,509,514Antibodies comprising chimeric constant domainsBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 23, 202512,503,520Compositions and methods for making antibodies based on use of an expression-enhancing locusBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 23, 202512,502,429Methods for treating atopic dermatitis by administering an IL-4R antagonistPharmaceuticalsRegeneron Pharmaceuticals, Inc.
Dec 16, 202512,497,460Anti-MSR1 antibodies and methods of use thereofPharmaceuticalsRegeneron Pharmaceuticals, Inc.
Dec 16, 202512,496,470Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 2, 202512,486,335Mice that make VL binding proteinsBiotechnologyRegeneron Pharmaceuticals, Inc.
Nov 25, 202512,480,955Deglycosylation methods for electrophoresis of glycosylated proteinsAnalysis of biological materialsRegeneron Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388890ASS1 Gene Insertion For The Treatment Of Citrullinemia Type IBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 25, 20252025/0388685METHODS FOR TREATING CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONISTPharmaceuticalsRegeneron Pharmaceuticals, Inc.
Dec 25, 20252025/0386809COMMON LIGHT CHAIN MOUSEBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 25, 20252025/0386808NON-HUMAN ANIMALS EXPRESSING EXOGENOUS TERMINAL DEOXYNUCLEOTIDYLTRANSFERASEBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 18, 20252025/0382636COMPOSITIONS FOR MAINTAINING LENTIVIRAL VECTOR AND USES THEREOFBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 18, 20252025/0382377ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOFPharmaceuticalsRegeneron Pharmaceuticals, Inc.
Dec 18, 20252025/0381303CRISPR INTERFERENCE THERAPEUTICS FOR C9ORF72 REPEAT EXPANSION DISEASEBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 18, 20252025/0381219HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-PLATINUM CHEMOPROTECTANT AGENTPharmaceuticalsDecibel Therapeutics, Inc.
Dec 11, 20252025/0376667ENGINEERED ALPHA KLOTHO POLYPEPTIDES AND USES THEREOFBiotechnologyRegeneron Pharmaceuticals, Inc.
Dec 11, 20252025/0376524TETRAVALENT MULTISPECIFIC BINDING MOLECULES AND METHODS OF USE THEREOFBiotechnologyRegeneron Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 201 · Biotechnology 191 · Measurement 47 · Medical technology 37 · Analysis of biological materials 21 · Computer technology 18.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton REGN · research, not advice